European Cancer Organisation


Friday 7 September 2018

12:00 - 13:15

Introductory Session: An ambitious agenda on cancer in Europe


In the wake of eurosceptic challenge, there is heightened impetus for the EU to ensure strong connection to the common aspirations of the citizen. Can a reenergised EU cancer agenda provide fresh demonstration of the benefits of structured cooperation between European countries? What should a more ambitious European agenda on cancer look like and consist of? What have we learned so far, and can examples from elsewhere, such as the USA’s Cancer Moonshot initiative, provide instructive lesson? 

Session Co-Chairs: Dr Ian Banks and Prof Philip Poortmans 

Speakers include:

Dr Vytenis Andriukaitis
EU Commissioner for Health & Food Safety
View Presentation

Her Excellency Marie-Louise Coleiro Preca (Video address)
President of Malta
View Presentation

Dr Dinah Singer
National Institute of Health, USA
View Presentation

Prof Mark Lawler
Queen's University Belfast, United Kingdom
View Presentation

Alojz Peterle MEP
President, MEPs Against Cancer

13:15 - 15:00

Outcomes Research: Adopting a 20 year mindset – the paradigm shift required


With cancer incidence rates expected to grow by 68% worldwide between 2012 and 2030, matching the promise of new science and treatment options with continually constrained public finance points to a more value-based landscape for rewarding innovation. It is right to demand more evidence and further certainty in respect to the real life benefits and outcomes achieved by current and potential models and modes of cancer care. It is to this need that outcomes research is addressed, a branch of public health research, which studies the outcomes of the structure and processes of the health care system on the health and well-being of patients and populations.

Yet obstacles remain in the path of progress, with identifiable gaps in the data infrastructure, research landscape, and international multi-stakeholder agreement on matters such as data sharing, ownership and protection.

Prof Richard Sullivan (Session Chair)
Kings College London, United Kingdom
View Presentation

Dr Claudia Allemani
London School of Hygiene and Tropical Medicine, UK

Dr John O'Donnell
Global VP, Health Economics and Outcomes Research, Bristol-Myers Squibb, USA
View Presentation

Dr Bettina Ryll
Melanoma Patient Network Europe, Sweden
View Presentation

Assigned intervention from 

Julia Levy

Collaboration for Oncology Data in Europe (CODE), United Kingdom

Dr Miroslav Mikolášik MEP
Member of ENVI Committee, European Parliament

15:00 - 15:30

Refreshment Break

15:30 - 17:30

Big Data – who’s in charge?


Stakeholders recognise the benefits big data can bring to research and improvement of care and treatment for cancer. However its full realisation is unlikely to occur without leadership, responsibility, strategy, direction and implementation.

What aspects of leadership and responsibility appear to be presently missing in terms of bringing big data opportunities to fruition, to whom should these leadership roles be assigned, and where does accountability reside? Implicit within this discussion is considered reflection on whether the realisation of a big data-driven future in research requires the strong hand of government-led efforts, or whether responsibilities are of a more shared and distributed nature?

Prof Mark Lawler (Session Chair)
Queen's University Belfast, United Kingdom
View Presentation
View Presentation

Jan Geissler
CML Advocates Network, Germany
View Presentation

Dr Denis Lacombe
Director General, EORTC, Belgium
View Presentation

Dr Clifford Hudis
CEO, American Society of Clinical Oncology (ASCO)
View Presentation

Prof Eva Morris
University of Leeds, United Kingdom
View Presentation

17::30 - 17:40 Launch of 'A new era in Cancer Care'
 17:40 Welcome Reception

Saturday 8 September 2018

9:00 - 10:30

Improving efficiency in cancer care: how can multidisciplinarity make a difference?


  • Highlighted latest research from All.Can on patient experience and perspective in respect to inefficiency in cancer care and opportunities for improvement

  • Explored the role of multidisciplinary cancer care in  addressing inefficiency in cancer care (e.g. reducing delays and unnecessary interventions, and improving outcomes)

  • Reflected on conclusions from 2018 research on waste and inefficiency in cancer care by the Swedish Institute for Health Economics (IHE)

Prof Peter Naredi (Session Chair)
View Presentation

Kathy Oliver
International Brain Tumour Alliance, UK
View Presentation

Prof Bengt Jonsson
Stockholm School of Economics, Sweden
View Presentation

Amadou Diarra
Global VP Policy Advocacy & Government Affairs, Bristol-Myers Squibb, USA
View Presentation

Dr Monica Bertagnolli
ASCO President, USA
View Presentation

Prof Hideo Baba
Japan Society of Clinical Oncology
View Presentation

10:30 - 11:00

Coffee Break

11:00 - 12:30

Integration of cancer care: the essential requirements


It is recognised that a multi-disciplinary and patient-centric approach is required to achieve integrated cancer care, central to attaining the best outcomes and quality of care for patients. But how do we move beyond the shared aspiration of integrated cancer care, to its real-life practice in daily reality? ECCO and primary care partner organisations have grappled with this question as part of a project to define “the essential requirements for primary care interventions throughout the cancer care pathway”. The outcomes of this work was presented at the session, before inviting participants at the Summit to help finalise consensus resolutions on the topic.

The resolutions included time-based targets for improvement, supported by assignment of responsibilities for achieving the goal, and underpinned by tools to aid implementation.

Dr Ian Banks (Session Co-Chair)
ECCO Patient Advisory Committee Chair, Belgium
View Presentation

Prof Peter Selby (Session Co-Chair)
University of Leeds, UK
View Presentation

Dr Tit Albreht
National Institute of Public Health, Slovenia
View Presentation

Prof David Weller
University of Edinburgh, UK
View Presentation

Dr Agnieszka Kolacinska
European Society of Surgical Oncology (ESSO)
View Presentation

Prof Alain Astier
European Society of Oncology Pharmacists (ESOP)
View Presentation


12:30 - 13:30


13:30 -15:00

Quality in cancer care: how to demand it, measure it and implement it


We all want quality cancer care, but how can we describe what it consists of, acquire a reliable measure of the level of quality of cancer care being delivered, and succeed in implementing improvement?

To these three questions a range of expert contributors shared insights and advice ahead of the audience being invited to vote on a series of Summit resolutions intended to provide answers. The resolutions included time-bound goals, assignment of responsibilities for their delivery, and a publicly available toolkit to support their implementation. Please visit here for further information.

Important reference was made during the session to the ECCO Essential Requirements for Quality Cancer Care (ERQCCs) as well as the activities of the Innovative Partnership on Action against Cancer (iPAAC) in respect to improving governance of cancer care.

Dr Alberto Costa (Session Co-Chair)
European School of Oncology, Italy

Geoffrey Henning (Session Co-Chair)
View Presentation

Prof Gunnar Saeter
View Presentation

Dr Luciana Neamtiu
European Commission, Belgium
View Presentation

Ellen Griesshammer
German Cancer Society, Germany
View Presentation

Dr Reg Waldeck
Oncology Market Access Strategy Leader, Bayer, USA
View Presentation


15:00 - 15:30

Coffee Break

15:30 - 17:30

Access and Value: It's about the entire cancer pathway


Led by Professor Yolande Lievens (Past-President, ESTRO), ECCO brought together a core group of experts to identify and reflect on existing methodologies for assessing value in respect to new pharmaceutical treatments. Following critical evaluation of the scales, including points of commonality and difference, the group shared their initial reflections and recommendations about the application of value based healthcare principles more holistically, including, but not limited to, non-systemic oncology treatments such as surgery and radiotherapy. 

The existing value frameworks used in the oncology setting that have been assessed by the project include the ASCO Value Framework, the ESMO Magnitude of Clinical Benefit Scale and the NCCN Evidence Blocks.

The session will share the initial reflections on these value scales and invite wider stakeholder and audience contribution to the debate ahead of commencing a further stage of the project, which may include fuller articulation of a value scale that can translate for use in non-systemic oncology treatments.

The session provided opportunity for more general consideration of the value based healthcare agenda, its progression so far, policy learning from experiences of its application in different countries and settings, and desirable developments for the future.

Prof Richard Sullivan (Session Chair)

Prof Philip Poortmans (Concluding Remarks) 

Prof Yolande Lievens
Past President of the European Society for Radiotherapy and Oncology (ESTRO)
View Presentation

Prof Riccardo Audisio
Past President of the European Society of Surgical Oncology (ESSO)
View Presentation

Dr Ajay Aggarwal
Institute of Cancer Policy, King’s College London
View Presentation

Kathy Oliver
International Brain Tumour Alliance, UK
View Presentation

Nicole Denjoy
View Presentation

Vanessa Schaub
F. Hoffmann-La Roche, Switzerland
View Presentation

Part 2 of the session examined how the role of professional care to cancer patients, and other interventions, can be better valued and recognised within national health systems.

Dr Carole Farrell
European Oncology Nursing Society (EONS)
View Presentation

Prof Lorenzo Derchi
President of the European Society of Radiology
View Presentation

Dr Maria Die Trill
President of the International Psycho-Oncology Society (IPOS)
View Presentation


17:30 - 17:45

 Coffee Break


17:45 - 19:15

Putting a price on cancer medicines: the challenges and prospective solutions


The good news? Scientific advances are bringing forward new hope for cancer patients through emerging novel forms of treatment such as immunotherapy, targeted therapy and precision medicine. The bad news? Countries around the world continue to struggle with the headache of how to meet their cost.

This Summit session invited a range of stakeholders to spell out the top challenges in the current pharmaceutical pricing and access environment, presenting concrete proposals for improvement.

Summit attendees voted to record their preferences and responses to the proposals made.

Session chair: Dr Ian Banks

Eveline Scheres
Chair of the ECL Access to Cancer Medicines Taskforce
View Presentation

Nathalie Moll
Director General of the European Federation of Pharmaceutical Industries and Associations (EFPIA)
View Presentation


20:00 - 22:30

Networking Dinner at Festival Hall at the City Hall, Vienna

Entrance Lichtenfelgasse 2 
Feststiege 1, 1010 Vienna


Sunday 9 September 2018

09:00 - 10:30

Survivorship: The next frontier of cancer care improvement


The ECCO 2018 European Cancer Summit session on Survivorship built upon the important policy leadership activity of ECCO member EORTC in this area, including its biennial Survivorship Summit

Hearing from cancer survivors, legal experts and academics, the session:
  • paid particular attention to the matter of financial discrimination encountered by cancer survivors,
  • highlighted available means of policy redress, such as the French Government’s enactment of legal reforms to enshrine a ‘right to be forgotten’ for cancer patients in respect to what they are obliged to declare to loan providers and insurers
  • encouraged the expression by stakeholders of consensus ambitions for reducing financial discrimination encountered by cancer survivors across all European countries. More information here:

Prof Françoise Meunier (Session Chair)
EORTC, Belgium
View Presentation

Dr Marie Mesnil
University of Rennes, France
View Presenation

Šarunas Narbutas
Youth Cancer Europe
View Presentation

Janette Rawlinson
Cancer survivor and Patient Advocate, UK
View Presentation

Assigned interventions from 

Carina Schneider

Childhood Cancer International Europe (CCI-Europe)

Alex Filicevas
European Cancer Patient Coalition (ECPC)



Patrick Johnston Memorial Lecture

Prof Françoise Meunier
EORTC, Belgium
View Presentation



Close of the Summit